HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Monograph Woes No Surprise To FDA Commissioner Nominee Gottlieb

This article was originally published in The Pink Sheet

Executive Summary

Gottlieb was asked only one question about OTC drug regulation during his confirmation hearing before the Senate HELP Committee, but it covered a large part of FDA's current concerns about the OTC market.

You may also be interested in...



With High Profile At FDA, Gottlieb Headed Ambitious Consumer Health Initiatives

Scott Gottlieb claimed higher profile than most previous FDA commissioners with frequent Twitter posts and by including his remarks in many agency communications to industries and consumers. In his nearly two years in post, he also had more central role in FDA initiatives in areas such as keeping unsafe products labeled as supplements off the market and explaining why hemp and CBD are available and supplements even though FDA considers the products noncompliant as dietary ingredients.

Gottlieb's Confirmation: He's Willing To Disagree With Trump, Sec. Price

Democrats test US FDA commissioner nominee's willingness to defend agency independence during confirmation hearing and probe potential conflicts of interest.

OTC Monograph Reform, User Fee Legislation Coming 'Any Day' – CHPA

Imminent OTC monograph reform legislation signals an agreement between industry and FDA on details of a proposal, which also includes a potential user fee program. CHPA also is hopeful for legislation restoring direct OTC drug purchases with pre-tax savings accounts.

Related Content

Topics

UsernamePublicRestriction

Register

RS122755

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel